#RESMAIN - Twitter Hashtag

almost 3 years ago

Listen to Jason Loveridge, CEO of @4SC_AG, chat to Optimum’s Eva Haas on the company’s breakthrough #RESMAIN data for #Kinselby, its maintenance therapy for treating Cutaneous T-cell lymphoma #CTCL patients https://t.co/emM9enmu8n 🎙️Subscribe today!

0

2

0

160

Michael Mayer @Papamicha007

over 3 years ago

Interessant - #Resminostat erreicht in #RESMAIN-Studie von #4SC primären Endpunkt bei kutanem T-Zell-Lymphom (CTCL) - aber: Resminostat erreicht den wichtigsten sekundären Endpunkt - Zeit bis zur Verschlechterung der Symptome (Juckreiz) – nicht -> https://t.co/UROdNAJGdd

0

2

0

390

1stOncology @1stOncology

over 7 years ago

#4SC’s pivotal #RESMAIN study of resminostat in #CTCL receives second positive safety review $4SC https://t.co/ksUR1g10TE

0

1

0

4SC @4SC_AG

almost 8 years ago

Significant milestone reached with enrollment of 100 patients in pivotal #RESMAIN study of #resminostat as #CTCL maintenance therapy https://t.co/CjuYTpZ2YM

0

2

3

0

4SC @4SC_AG

over 8 years ago

4SC AG: Yakult Honsha schließt ersten japanischen Patienten in gemeinsame zulassungsrelevante #RESMAIN-Studie für #Resminostat in #CTCL ein https://t.co/piOhb91wml

0

1

0

4SC @4SC_AG

over 8 years ago

One third of patients enrolled according to plan in pivotal study #RESMAIN of #resminostat in #ctcl. Topline results expected in H1 2019 https://t.co/WCrkJ4xsnO

0

1

0

4SC @4SC_AG

over 8 years ago

Ein Drittel der Patienten in zulassungsrelevanter Studie #RESMAIN mit #Resminostat in #CTCL rekrutiert. Erste Daten in H1 2019 erwartet https://t.co/WCrkJ4xsnO

0

1

0